Current and target prices
| Drug | Indication | Patent expiry | Current UK drug price per month (UK)* | Target price per month |
|---|---|---|---|---|
| Bortezomib39 | 1st line MM | 2014–22 | £762.38 | £199.92 |
| Dasatinib40 | 1st line CML | 2020–26 | £2504.96 | £9.43 |
| Dasatinib41 | 2nd line CML | 2020–26 | £2504.96 | £9.43 |
| Everolimus42 | 2nd line RCC | 2019–25 | £2970.00† | £851.65 |
| Everolimus43 | Breast CA | 2019–25 | £2970.00 | £851.65 |
| Gefitinib44 | 1st line NSC lung CA | 2017 | £2167.71† | £10.26 |
References for patent expiry dates in online supplementary appendix A.
*Monthly costs calculated using price from latest version of BNF Online.45
†A Patient Access Scheme (PAS) is in place for this drug. The PAS was not included in our calculations.
CA, cancer; CML, chronic myeloid leukaemia; MM, multiple myeloma; NSC, non-small cell; RCC, renal cell carcinoma.